Climb Bio, a clinical-stage biotech company, will present new Phase 1b clinical trial data for budoprutug, an anti-CD19 monoclonal antibody, targeting immune thrombocytopenia (ITP) at the 68th American Society of Hematology Annual Meeting in December 2026. The data will cover safety, B-cell depletion, and platelet responses from all dose cohorts in previously treated ITP patients. Budoprutug shows promise in treating B-cell mediated immune diseases and is also being tested for other conditions like primary membranous nephropathy and systemic lupus erythematosus. This presentation highlights Climb Bio's ongoing efforts to develop novel therapies for immune-mediated diseases, with further clinical development expected.
Climb Bio's new clinical data presentation coincides with a strong market showing in the health sector, where 127 of 150 US stocks rose on the day. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 20:41 WIB: HCA Health Inc rose 7.16% to USD 496.00 with a typical hold time of 77 days, Medline Inc. Class A gained 7.10% to USD 36.51 with 98% buy orders and a 9-day hold time, while Tenet Healthcare Corporation fell 5.94% to USD 282.52 with 100% sell orders and a 17-day hold time.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
